deltatrials
Terminated PHASE2 NCT00118066

Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia

A Randomized Phase II Trial Of Calcitriol In Patients With Prostatic Intraepithelial Neoplasia

Sponsor: National Cancer Institute (NCI)

Conditions Precancerous/Nonmalignant Condition Prostate Cancer
Interventions calcitriol observation
Updated 6 times since 2017 Last updated: May 22, 2015 Started: May 31, 2004 Primary completion: Jun 30, 2011 Completion: Aug 31, 2011

A PHASE2 clinical study on Precancerous/Nonmalignant Condition and Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Rutgers Cancer Institute of New Jersey
  • Rutgers, The State University of New Jersey
Data source: Rutgers, The State University of New Jersey

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • East Brunswick, United States
  • • Morristown, United States
  • • New Brunswick, United States
  • • Summit, United States